29.41

6.40% 1.77

After Hours: 29.50 0.09 +0.31%

Arrivent Biopharma Inc (AVBP)

Overview News Price History Discussions Forecast

Arrivent Biopharma Inc stock is traded at $29.41, with a volume of 594.29K. It is up +6.40% in the last 24 hours and up +23.05% over the past month. ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.

Previous Close:

$27.64

Open:

$27.71

24h Volume:

594.29K

Relative Volume:

1.18

Market Cap:

$1.30B

Revenue:

Net Income/Loss:

$-166.31M

P/E Ratio:

-6.5939

EPS:

-4.4602

Net Cash Flow:

$-160.59M

1W Performance:

+16.48%

1M Performance:

+23.05%

6M Performance:

+42.91%

1Y Performance:

+57.86%

1-Day Range:

$27.71

$29.49

1-Week Range:

$25.17

$29.49

52-Week Range:

$16.10

$29.49

Arrivent Biopharma Inc Stock (AVBP) Company Profile

Name

Arrivent Biopharma Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

240-780-6356

Address

18 CAMPUS BLVD., NEWTOWN SQUARE

Employee

Twitter

Next Earnings Date

2026-03-04

Latest SEC Filings

AVBP's Discussions on Twitter

Compare AVBP vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AVBP Arrivent Biopharma Inc	29.41	1.22B	0	-166.31M	-160.59M	-4.4602
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-12-26	Resumed	BTIG Research	Buy
Dec-10-25	Initiated	BTIG Research	Buy
Nov-25-25	Initiated	Truist	Buy
Jul-10-25	Resumed	Goldman	Buy
Mar-20-25	Initiated	B. Riley Securities	Buy
Mar-10-25	Initiated	Guggenheim	Buy
Jul-22-24	Initiated	Oppenheimer	Outperform
Apr-30-24	Initiated	H.C. Wainwright	Buy
Feb-20-24	Initiated	Citigroup	Buy
Feb-20-24	Initiated	Goldman	Buy
Feb-20-24	Initiated	Jefferies	Buy

View All

Arrivent Biopharma Inc Stock (AVBP) Latest News

02:14 AM

Are you looking for a top momentum pick? Why ArriVent BioPharma, Inc. (AVBP) is a great choice - MSN

02:14 AM

10:06 AM

Are medical stocks lagging ArriVent BioPharma, Inc. (AVBP) this year? - MSN

10:06 AM

Apr 14, 2026

Understanding Momentum Shifts in (AVBP) - Stock Traders Daily

Apr 14, 2026

Wall Street analysts think ArriVent BioPharma, Inc. (AVBP) could surge 72.44%: Read this before placing a bet - MSN

Apr 14, 2026

Apr 13, 2026

Are Medical Stocks Lagging AstraZeneca (AZN) This Year? - Yahoo Finance

Apr 13, 2026

Apr 11, 2026

Guggenheim Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $45 - Moomoo

Apr 11, 2026

Apr 09, 2026

Surprises Report: How does SAPH compare to its peers2026 Macro Impact & AI Based Buy/Sell Signal Reports - baoquankhu1.vn

Apr 09, 2026

Arrivent Biopharma stock hits 52-week high at 27.25 USD By Investing.com - Investing.com Australia

Apr 09, 2026

Arrivent Biopharma stock hits 52-week high at 27.25 USD - Investing.com

Apr 09, 2026

Apr 06, 2026